UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2022 Or (626) 303-7902 (Registrant's Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive STAAR SURGICAL COMPANY Lake Forest, California 92630 ☐ TRANSITI ...

STAAR Surgical Company (NASDAQ:STAA) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Brian Moore - Vice President, Investor, Media Relations and Corporate Development Caren Mason - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Bill Plovanic - Canaccord Zach Weiner - Jefferies Ryan Zimmerman - BTIG Chris Cooley - Stephens Andrew Brackmann - William Blair David Saxon - Needham Disclaimer*: This transcript is designed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 1, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic O ...

Financial Data and Key Metrics Changes - Total net sales for Q4 2021 were $59 million, up 28% compared to $46 million in Q4 2020 and up 1% sequentially from Q3 2021 [19] - Gross profit for Q4 2021 was $45 million, or 76.3% of net sales, compared to $34.3 million, or 74.6% of net sales in Q4 2020 [22] - Net income in Q4 2021 was $4.9 million, or $0.10 per diluted share, compared to $3.3 million, or $0.07 per diluted share in Q4 2020 [29] Business Line Data and Key Metrics Changes - ICL sales represented 90% of total company net sales for Q4 2021, up from 87% in the prior year quarter [21] - ICL unit growth for fiscal 2021 was up 48% year-over-year, significantly outpacing the 17% increase in global industry refractive procedures [10] Market Data and Key Metrics Changes - ICL unit growth in various markets for Q4 2021 included China up 44%, Japan up 45%, South Korea up 35%, India up 74%, and Latin America up 30% compared to the prior year quarter [11] - The U.S. is estimated to have 100 million adults aged 21 to 45 who are potential candidates for implantable Collamer lenses [15] Company Strategy and Development Direction - The company plans to invest more heavily in consumer awareness programs to accelerate the shift to lens-based vision correction [15] - STAAR aims to triple its manufacturing capacity within the next 18 months to meet growing demand [57] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed the fiscal 2022 net sales outlook of approximately $295 million, representing 28% year-over-year growth [13] - The company expects to return to a more normal pre-pandemic sales calendarization in 2022, with approximately 48% of net sales in the first half of the year [20] Other Important Information - The company anticipates a gross margin of approximately 77% for Q1 and full year 2022, with investments in manufacturing facilities [23] - Capital expenditures for 2022 are expected to be approximately $20 million, primarily for manufacturing expansion [31][76] Q&A Session Summary Question: Update on discussions with the FDA - Management is in customary interactive review with the FDA and feels confident about a positive result for their submission [36] Question: Impact of the Olympics on branding opportunities in China - Management noted strong orders from surgeons in China and attributed growth to effective social media and digital marketing efforts [37] Question: Current backlog status and its impact on guidance - Management confirmed a healthy backlog and indicated that some of it is factored into the 2022 guidance, with strong current orders providing an opportunity to overperform [42] Question: Capacity and supply chain issues - Management is working to triple current capacity within 18 months and aims to have reserve inventory capability of 30% to 40% of projected demand [57] Question: Tax rate expectations for 2022 - The anticipated tax rate for 2022 is approximately 30%, influenced by the geographical mix of profitability [77] Question: Continuation of COVID impacts on guidance - Management has taken potential COVID-related headwinds into account but remains optimistic about a strong start to 2022 [82] Question: FDA requirements for manufacturing expansions - Management explained that some expansions require inspections while others may only need notification, depending on regulatory requirements [87]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (Registrant's telephone number ...

Financial Data and Key Metrics Changes - Total net sales for Q3 2021 were $58.4 million, up 24% compared to $47.1 million in Q3 2020, exceeding the previous outlook of $57 million to $58 million [25][26] - Gross profit for Q3 2021 was $45.3 million, or 77.6% of net sales, compared to 74.1% in Q3 2020 [28] - Net income in Q3 2021 was $6 million, or $0.12 per diluted share, compared to $3.9 million, or $0.08 per share in Q3 2020 [35][36] Business Line Data and Key Metrics Changes - ICL sales represented 93% of total company net sales for Q3 2021, with other products accounting for 7% [27] - Global ICL sales growth was up 31% year-over-year, with expectations for Q4 to exceed 40% growth [26][24] Market Data and Key Metrics Changes - ICL unit growth by geography included: Japan up 44%, South Korea up 21%, India up 338%, Germany up 25%, European distributor markets up 22%, Middle East and North Africa up 242%, and the U.S. up 66% compared to the prior year quarter [16] - China remains the largest market, with distributor inventory levels drawn down to historically low levels to meet demand [11] Company Strategy and Development Direction - The company is raising its full-year fiscal 2021 net sales outlook to a range of $230 million to $231 million, representing over 40% year-over-year growth [24] - Strategic imperatives include increasing marketing investments in key U.S. cities and expanding engagement with surgeons [19][21] - The company plans to open an ICL Experience Center in California in the first half of 2022 to enhance surgeon training and marketing education [23] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming temporary supply chain challenges and anticipates catching up on backlog in Q4 and Q1 2022 [50][54] - The company remains optimistic about achieving a compound annual growth rate of over 25% from 2020 to 2022, despite the impact of COVID-19 [24][68] Other Important Information - Cash and cash equivalents as of October 1, 2021, totaled $196.2 million, up from $152.5 million at the end of Q4 2020 [37] - The company plans to participate in several upcoming investor events, including the Canaccord Genuity Virtual MedTech & Diagnostics Forum [38] Q&A Session Summary Question: Regarding the backlog of 20,000 lenses - Management confirmed that the majority of the backlog is related to China and estimated that it could represent at least $65 million in revenue for the quarter if shipped [42] Question: Timing for distributor restocking - Management indicated that replenishment of inventory in China is already underway and they are prepared for the next big season starting in January [45] Question: Supply chain issues and their impact - Management clarified that the supply chain issues were not exclusive to China but were managed effectively to meet critical demand [88] Question: Expectations for U.S. market penetration post-launch - Management aims to achieve at least 20% market share in the U.S. within two to three years post-approval [95] Question: Growth driven by refractive market versus conversions - Management stated that the refractive market grows in the mid-single digits, while the company is growing at least 25% plus, indicating market share gains [82]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2021 were $62.4 million, up 77% compared to $35.2 million in Q2 2020, and up 23% sequentially from Q1 2021 [26][34] - Gross profit for Q2 2021 was $49.2 million, representing 78.9% of net sales, compared to 69.4% in Q2 2020 [28] - Operating income in Q2 2021 was $10.7 million, or 17.2% of net sales, compared to an operating loss of $600,000 in Q2 2020 [33] - Net income for Q2 2021 was $8.6 million, or $0.17 per diluted share, compared to a net loss of $1.2 million in Q2 2020 [34] Business Line Data and Key Metrics Changes - Global ICL unit growth for Q2 2021 was up 79% year-over-year, driving net sales growth [11] - ICL sales represented 95% of total company net sales for Q2 2021, with other products making up 5% [27] - The year-over-year increase in net sales for Q2 2021 was primarily due to global ICL sales growth, which was up 93% [26] Market Data and Key Metrics Changes - In China, ICL unit growth was up 65%, while Japan saw a 95% increase, and South Korea experienced a 57% rise [11] - The U.S. market reported a 255% increase in ICL sales year-over-year [11] - The Middle East and North Africa saw a staggering 378% growth in ICL sales [11] Company Strategy and Development Direction - The company is focusing on premium lens-based business and greater revenue per procedure, anticipating a shift from laser vision correction to ICL [18] - STAAR is increasing its net sales outlook for the full year fiscal 2021 to a range of $227 million to $230 million, up from a previous outlook of $215 million to $217 million [24] - The company is preparing for broader commercialization of the EVO lens and continues to work on regulatory pathways for marketing approval outside of Europe [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth opportunities, citing a third-party research firm naming STAAR the fastest-growing company in ophthalmology [22] - The company remains mindful of ongoing COVID-19 challenges but is optimistic about continued demand for EVO lenses [23] - Management highlighted the importance of in-person trade shows and conferences for advancing commercialization strategies [20] Other Important Information - Cash and cash equivalents as of July 2, 2021, totaled $173.1 million, up from $152.5 million at the end of Q4 2020 [36] - The company plans to participate in several investor conferences in the coming weeks [37] Q&A Session Summary Question: Comments on the dynamics between laser vision correction and ICL in China and Europe - Management noted that ICL is gaining ground among moderate myopia patients, with studies supporting higher patient satisfaction compared to laser vision correction [42] Question: Expectations for revenue building for the U.S. launch of EVO - Management indicated strong enthusiasm from surgeons for the EVO lens and expects significant market share growth similar to past experiences in China [51][53] Question: Plans for training U.S. surgeons for EVO - Management confirmed that training materials and certification requirements are ready, and they do not foresee training as a limiting factor [92] Question: Impact of COVID variants on business in China and Japan - Management reported limited disruptions in China due to COVID, while Japan experienced a slight decrease in lens implants during the Olympics, but expects a return to normal [64] Question: Future of current Visian ICL lenses post-EVO approval - Management stated that current Visian ICL lenses will continue to be sold alongside EVO due to the advantages of the new lens [68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Oc ...

Financial Data and Key Metrics Changes - Total net sales for Q1 2021 were $50.8 million, up 44% compared to $35.2 million in Q1 2020 and up 10% sequentially from Q4 2020 [14] - Gross profit for Q1 2021 was $39.1 million or 77.1% of net sales, compared to $24.8 million or 70.4% of net sales in Q1 2020 [16] - Net income in Q1 2021 was $5 million or $0.10 per diluted share, compared to a net loss of $134,000 in Q1 2020 [20] Business Line Data and Key Metrics Changes - ICL sales represented 93% of total company net sales for Q1 2021, with strong growth across various regions [14] - Global ICL unit growth for Q1 2021 was up 54% year-over-year, with significant increases in China (up 63%), Japan (up 72%), and the US (up 46%) [6][14] Market Data and Key Metrics Changes - The company anticipates Q2 2021 net sales to be approximately 50% year-over-year revenue growth compared to Q2 2020 [14] - The US market is expected to see a significant introduction of EVO lenses pending FDA approval, with a planned launch in Q4 2021 [12][21] Company Strategy and Development Direction - The company is focusing on expanding its EVO Visian ICL family of lenses and enhancing direct-to-consumer outreach to build awareness [8][10] - A new advertising campaign featuring a Japanese celebrity aims to increase visibility and patient engagement in Japan [9] Management's Comments on Operating Environment and Future Outlook - Management views the current growth as a continuation of pre-COVID momentum, with expectations for sustained growth in the coming quarters [24][25] - The company anticipates total net sales for fiscal 2021 to be approximately $215 million to $217 million, representing over 30% year-over-year growth [13] Other Important Information - The company plans to participate in several upcoming conferences, including the Oppenheimer Medtech Tools and Diagnostic Summit [21] - The company expects to maintain gross margins in the mid-70% range for Q2 and the fiscal year 2021 [16] Q&A Session Summary Question: Source of growth and awareness - Management does not see the growth as a catch-up but as a continuation of momentum pre-COVID, with strong patient referrals and social media engagement driving awareness [24] Question: US and EU implant numbers - Management noted a significant uptake in Europe and the US, attributing it to prior efforts in building awareness and patient satisfaction [25]